STROBE Statement —checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1, Line 4	Running title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3, Line 35-59	Abstract
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 5, Line 66-84	Introduction, Paragraph 1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5-6, Line 85-92	Introduction, Paragraph 3
Methods				
Study design	4	Present key elements of study design early in the paper	Page 6, Line 96-97	Study population, Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6, Line98-100	Study population, Paragraph 1
Participants	6	(a) ***Cohort study*** —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study*** —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study*** —Give the eligibility criteria, and the sources and methods of selection of participants	Page 6, Line 98-105/Page 8, Line 140-145	Study population, Paragraph 1/Outcomes,Paragraph 6
		(b) ***Cohort study*** — For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study*** — For matched studies, give matching criteria and the number of controls per case	N/A	The current study was not designed as matched studies
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 7-8, Line 111-148	Coronary angiography, Echocardiography, Outcomes, Paragraph 3-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 7-8, Line 111-137	Coronary angiography, Echocardiography, Paragraph 3-5
Bias	9	Describe any efforts to address potential sources of bias	N/A	None
Study size	10	Explain how the study size was arrived at	N/A	None
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page -7-8, Line 129-137	Echocardiography, Paragraph 5

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 9, Line 151-169	Statistical analysis, Paragraph 7
		(b) Describe any methods used to examine subgroups and interactions	Page 9, Line 156-160	Statistical analysis, Paragraph 7
		(c) Explain how missing data were addressed	N/A	Exclusion
		(d) ***Cohort study*** — If applicable, explain how loss to follow-up was addressed ***Case-control study*** — If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study*** — If applicable, describe analytical methods taking account of sampling strategy	N/A	Exclusion
		(e) Describe any sensitivity analyses	N/A	None
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study —eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 10, Line 172-179	Paragraph 1-2
		(b) Give reasons for non-participation at each stage	Page 10, Line 172-175	Paragraph 1
		(c) Consider use of a flow diagram	Page 10, Line 176	Paragraph 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 10-11, Line 182-194	Population Characteristics, Paragraph 3-4
		(b) Indicate number of participants with missing data for each variable of interest	N/A	None
		(c) ***Cohort study*** —Summarise follow-up time (eg, average and total amount)	Page 10, Line 177	Paragraph 2
Outcome data	15*	***Cohort study*** — Report numbers of outcome events or summary measures over time	Page 10, Line 177-179	Paragraph 2
		Case-control study — Report numbers in each exposure category, or summary measures of exposure	N/A	Cohort study
		Cross-sectional study — Report numbers of outcome events or summary measures	N/A	Cohort study
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 11, Line 197-212	EAS index as the main predictor for MACE and composite events, Paragraph 5-7
		(b) Report category boundaries when continuous variables were categorized	Page 11, Line 203-208	EAS index as the main predictor for MACE and composite events, Paragraph 6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	None
Other analyses	17	Report other analyses done —eg analyses of subgroups and interactions, and sensitivity analyses	Page 12, Line 215-219	ROC analyses for EAS index in predicting MACE events, Paragraph 8

Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 12, Line 222-225	Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 14, Line 266-272	Limitation, Paragraph 7

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 10-11, Line 193-219	EAS index and prognosis, Paragraph 2-5
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 12, Line 222-225	Implications and Significance, Paragraph 6
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 13, Line 251-256	Acknowledgments Funding

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www. annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/qims-23-109
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.